Genes News and Research

RSS

Schizophrenia brain changes 'due to disease rather than genes’

The brain abnormalities observed in patients with schizophrenia are primarily due to processes associated with the disease itself or its treatment, as opposed to being caused by genetic factors, the results of a Dutch study indicate.

1 Aug 2012

Orc1 mutations may explain pathology in manifestations of Meier-Gorlin syndrome

Research published Aug. 1 by scientists at Cold Spring Harbor Laboratory (CSHL) links gene mutations found in some patients with Meier-Gorlin syndrome (MGS) with specific cellular dysfunctions that are thought to give rise to a particularly extreme version of dwarfism, small brain size, and other manifestations of abnormal growth which generally characterize that rare condition.

1 Aug 2012

Researchers discover new approach to treat two lethal metastatic cancers

A potentially powerful new approach to treating two lethal metastatic cancers - triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer - has been discovered by researchers at Mayo Clinic in Florida.

1 Aug 2012

NYGC purchases four Life Technologies' Ion Proton Sequencers

Life Technologies Corporation today announced that the New York Genome Center (NYGC) has purchased four Ion Proton Sequencers for its new Innovation Center.

31 Jul 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Population Genetics validates GenomePooling™ for cancer

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

31 Jul 2012

Opioid receptors can control metabolic response to diets high in fat and sugar

Imagine eating all of the sugar and fat that you want without gaining a pound. Thanks to new research published in The FASEB Journal, the day may come when this is not too far from reality.

31 Jul 2012

High choline intake during pregnancy may improve how a child responds to stress

If you're sick from stress, a new research report appearing in the August 2012 issue of The FASEB Journal suggests that what your mother ate-or didn't eat-may be part of the cause.

31 Jul 2012

Researchers use computational analysis to identify new Achilles heel for drug-resistant breast cancer

Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

31 Jul 2012

GenomePooling™ method is sensitive and accurate

31 Jul 2012

Sleep problems linked to binge eating in women

Sleep problems are significantly associated with binge eating in women, study results show.

31 Jul 2012

TAU researcher reveals link between plant and human biology

Increasingly, scientists are uncovering surprising biological connections between humans and other forms of life. Now a Tel Aviv University researcher has revealed that plant and human biology is much closer than has ever been understood - and the study of these similarities could uncover the biological basis of diseases like cancer as well as other "animal" behaviors.

31 Jul 2012

EPHA3 mutations may be important drivers of lung cancers

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors.

31 Jul 2012

Gluconeogenesis severely compromised in HCC by IL6-Stat3-mediated activation of miR-23a

As liver cancer develops, tumor cells lose the ability to produce and release glucose into the bloodstream, a key function of healthy liver cells for maintaining needed blood-sugar levels.

31 Jul 2012

Researchers identify new genetic target for diuretic therapy

Researchers at the University of Cincinnati (UC) have identified a new genetic target for diuretic therapy in patients with fluid overload-like those with congestive heart failure, liver cirrhosis or kidney failure.

31 Jul 2012

Gene for sporadic paralysis of childhood discovered

Researchers have identified de novo mutations in the ATP1A3 gene that they believe are responsible for a sporadic childhood paralysis known as alternating hemiplegia of childhood.

30 Jul 2012

New research indicates molecular signaling from end to end in peripheral nerve cells

When the longest cells in the body are injured at their farthest reaches, coordinating the cells' repair is no easy task. This is in part because these peripheral nerve cells can be extremely long - up to one meter in adult humans - which is a lot of distance for a molecular distress signal to cover in order to reach the "command center" of the cell's nucleus.

30 Jul 2012

Study sheds light on complexities of cancer genetics

By studying fruit flies, scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have successfully devised a fast and cost-saving way to uncover genetic changes that have a higher potential to cause cancer.

30 Jul 2012

Evidence for ADHD due to delay in brain development

Is attention-deficit/hyperactivity disorder (ADHD) due to a delay in brain development or the result of complete deviation from typical development? In the current issue of Biological Psychiatry, Dr. Philip Shaw and colleagues present evidence for delay based on a study by the National Institutes of Health.

30 Jul 2012

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has earned a development milestone payment from GlaxoSmithKline, totaling $3.2 million. The milestone payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza vaccine.

30 Jul 2012